2-OHp-β-cyclodextrin Solution 10% (w/v)
| Catalog # |
K1010005D |
| Lot # |
Batch Dependent |
| Expiration |
Batch Dependent |
| Amount |
25 mL |
| Concentration |
10% (w/v) |
| Supplied as |
Solution |
| Applications |
Solubility enhancement, molecular assemblies, organic synthesis |
| Storage |
2–8°C |
| Keywords |
(2-hydroxypropyl)-β-cyclodextrin, 2-OHp-β-CD |
| Grade |
Biotechnology grade; ultrapure water, 0.22 µm filtered |
This 10% (w/v) solution of 2-hydroxypropyl-β-cyclodextrin (HPβCD) is a widely used reagent in pharmaceutical formulation, drug delivery, and supramolecular chemistry. HPβCD is a modified β-cyclodextrin with enhanced aqueous solubility and reduced toxicity, making it suitable for encapsulating hydrophobic compounds and improving their bioavailability. Its larger cavity size compared to α-cyclodextrin allows for complexation with a broader range of guest molecules.
Supplied in ultrapure water and filtered through 0.22 µm membranes, this biotechnology-grade solution is packaged in 25 mL aliquots and stored at 2–8°C. HPβCD is frequently used in antiviral research, cholesterol modulation, and nanoparticle stabilization. It has been studied for its effects on autophagy, membrane permeability, and pharmacokinetics, and is compatible with both in vitro and in vivo applications.
Key benefits:
- 10% (w/v) HPβCD solution for solubility enhancement and molecular encapsulation
- Supports drug delivery, lipid raft studies, and supramolecular chemistry
- Filtered through 0.22 µm for analytical and biological reproducibility
- Packaged in ultrapure water; biotechnology grade
- Compatible with pharmaceutical, biochemical, and nanomedicine workflows
Indication for Use:
This product is for Research Use Only (RUO). This product is not for administration to humans or animals. This product is not for human or veterinary diagnostic or therapeutic use.
References:
1: Sun H, Zong H, Wu G. 2‑Hydroxypropyl‑β‑cyclodextrin blocks autophagy flux and triggers caspase‑8‑mediated apoptotic cascades in HepG2 cells. Mol Med Rep. 2020 Sep;22(3):1901-1909.
2: Kao ML, Stellar S, Solon E, Lordi A, Kasica N, Swain G, Bagel JH, Gurda BL, Vite CH. Pharmacokinetics and distribution of 2-hydroxypropyl-β-cyclodextrin following a single intrathecal dose to cats. J Inherit Metab Dis. 2020 May;43(3):618-634.
3: Leonis G, Christodoulou E, Ntountaniotis D, Chatziathanasiadou MV, Mavromoustakos T, Naziris N, Chountoulesi M, Demetzos C, Valsami G, Damalas DE, Tzakos AG, Thomaidis NS, Karageorgos V, Liapakis G. Antihypertensive activity and molecular interactions of irbesartan in complex with 2-hydroxypropyl-β-cyclodextrin. Chem Biol Drug Des. 2020 Jul;96(1):668-683.
4: Ding Y, Pang Y, Vara Prasad CVNS, Wang B. Formation of inclusion complex of enrofloxacin with 2-hydroxypropyl-β-cyclodextrin. Drug Deliv. 2020 Dec;27(1):334-343.
5: Pons-Faudoa FP, Sizovs A, Di Trani N, Paez-Mayorga J, Bruno G, Rhudy J, Manohar M, Gwenden K, Martini C, Chua CYX, Varchi G, Marzinke MA, Grattoni A. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. J Control Release. 2019 Jul 28;306:89-96.
6: Stappaerts J, Berben P, Cevik I, Augustijns P. The effect of 2-hydroxypropyl-β-cyclodextrin on the intestinal permeation through mucus. Eur J Pharm Sci. 2018 Mar 1;114:238-244.
7: Liu X, Ding D, Chen GD, Li L, Jiang H, Salvi R. 2-Hydroxypropyl-β-cyclodextrin Ototoxicity in Adult Rats: Rapid Onset and Massive Destruction of Both Inner and Outer Hair Cells Above a Critical Dose. Neurotox Res. 2020 Oct;38(3):808-823.
8: Yu SC, Chen TC, Hou YT, Wan L, Tsai FJ, Tsai Y. β-Sitosterol-2-hydroxypropyl-β-cyclodextrin inclusion complex: Characterization and inhibitory effect on adipogenesis in 3T3-L1 pre-adipocytes. Steroids. 2018 Dec;140:196-201.
9: Burga-Sánchez J, Ferreira LEN, Volpato MC, Cabeça LF, Braga M, Fraceto LF, de Paula E, Groppo FC. Physicochemical characterization and cytotoxicity of articaine-2-hydroxypropyl-β-cyclodextrin inclusion complex. Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1313-1323.
10: Han D, Han Z, Liu L, Wang Y, Xin S, Zhang H, Yu Z. Solubility Enhancement of Myricetin by Inclusion Complexation with Heptakis-O-(2-Hydroxypropyl)-β-Cyclodextrin: A Joint Experimental and Theoretical Study. Int J Mol Sci. 2020 Jan 24;21(3):766.</
